Effects of total gonadotropin dose on embryo quality and clinical outcomes with AMH stratification in IVF cycles: a retrospective analysis of 12,588 patients

Table 1 Cycle characteristics of different Gn doses among the study population

Total Gn dosage(IU)	< 1875	1875–3750	≥ 3750	P Value
Cycles	4347	6458	1783
Female age (years)	29.18 ± 3.67	31.33 ± 4.47	34.35 ± 4.68	< 0.001
Female BMI (kg/m²)	20.90 ± 1.95	21.70 ± 1.94	21.86 ± 1.84	< 0.001
Serum AMH (ng/ml)	4.50 ± 1.82	2.81 ± 1.64	1.29 ± 0.77	< 0.001
Basal FSH (mIU/ml)	6.18 ± 1.45	7.09 ± 2.08	8.70 ± 3.50	< 0.001
Gn duration (days)	12.30 ± 1.45	13.41 ± 1.79	15.18 ± 1.93	< 0.001
Number of oocytes retrieved	16.73 ± 6.58	13.16 ± 6.22	8.03 ± 4.57	< 0.001
Number of MII	13.83 ± 5.95	10.68 ± 5.45	6.61 ± 4.09	< 0.001
Normal fertilization rate (%)	65.82	64.34	64.27	< 0.001
Average number of ET	1.62 ± 0.49	1.72 ± 0.45	1.75 ± 0.44	< 0.001
Stage of ET
Day 3 (%)	67.13	81.55	93.06	< 0.001
Day 5/6 (%)	32.87	18.45	6.94	< 0.001
Endometrial thickness on ET day	12.64 ± 2.63	12.42 ± 2.74	11.99 ± 2.73	< 0.001
Embryo quality
Top-day3 embryo rate (%)	70.67	67.34	66.03	< 0.001
Blastocyst formation rate (%)	60.27	53.76	43.04	< 0.001
High-quality blastulation rate (%)	22.20	18.09	12.18	< 0.001
Clinical outcome
Implantation rate (%)	57.27	45.46	31.70	< 0.001
Clinical pregnancy rate (%)	72.72	61.89	46.31	< 0.001
Live birth rate (%)	57.08	47.64	34.12	< 0.001

AMH anti-Müllerian hormone, Gn gonadotropin, BMI body mass index, FSH follicle-stimulating hormone, MII mature oocytes, ET embryo transfer. P < 0.05 indicates significant difference among the three Gn groups

ISSN: 2047-783X